Second Quarter Earnings Season Heats Up
This article was originally published in The Pink Sheet Daily
Amgen, J&J, Sanofi-Aventis, Pfizer, Merck, Roche, Lilly and Schering-Plough are scheduled to report results in upcoming week. Bristol could expand upon plans to sell OTC unit to Novartis the following week.
You may also be interested in...
The $660 mil. acquisition makes the Swiss firm a "more attractive" Rx-to-OTC switch partner, Novartis Consumer Health CEO Choffat says. Bristol's OTCs include Excedrin, Comtrex, Bufferin, No-Doz.
Acquisition of IMS Health will allow Netherlands-based VNU to move its health care marketing segment into physician targeting. The $7 bil. deal is expected to close in the first quarter of 2006.
Ag/FDA subcommittee had tabled FDA hearing pending confirmation of a permanent agency commissioner. House cleared FDA 2006 spending in early June.